Dr. Mark S. Kipnes, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1985, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license G7539 (first issued 1985; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 786 | 505 |
| Established patient office or other outpatient visit, 30-39 minutes | 663 | 469 |
| Blood test, comprehensive group of blood chemicals | 610 | 445 |
| Hemoglobin a1c level | 548 | 423 |
| Blood test, thyroid stimulating hormone (tsh) | 488 | 381 |
| Thyroxine (thyroid chemical), free | 478 | 372 |
| Blood test, lipids (cholesterol and triglycerides) | 447 | 366 |
| Vitamin d-3 level | 378 | 338 |
| Phosphate level | 337 | 308 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 293 | 248 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in San Antonio, TX | 41 |
| Levothyroxine Sodium Other prescribers in San Antonio, TX | 29 |
| Rosuvastatin Calcium Other prescribers in San Antonio, TX | 29 |
| Ezetimibe Other prescribers in San Antonio, TX | 21 |
| Metformin Hcl Er (metformin hcl) Other prescribers in San Antonio, TX | 20 |
| Synthroid (levothyroxine sodium) Other prescribers in San Antonio, TX | 17 |
| Losartan Potassium Other prescribers in San Antonio, TX | 17 |
| Metformin Hcl Other prescribers in San Antonio, TX | 15 |
| Jardiance (empagliflozin) Other prescribers in San Antonio, TX | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 78 payments worth $2,970 in total to this clinician.
| Mannkind Corporation | $1,407 |
|---|---|
| Sequel Med Tech, LLC | $296 |
| Corcept Therapeutics | $263 |
| Novo Nordisk Inc | $228 |
| Beta Bionics, Inc. | $154 |
| Dexcom, Inc. | $154 |
| Lilly USA, LLC | $71.83 |
| Soleno Therapeutics, Inc. | $54.24 |
| Food and Beverage | $1,497 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,275 |
| Travel and Lodging | $198 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) AFREZZA · DIABETES MEDICINE | $1,275 |
| Mannkind Corporation Jul 10, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $91.00 |
| Corcept Therapeutics May 1, 2025 | Travel and Lodging travel to AVENTURA, FL | $73.94 |
| Corcept Therapeutics May 2, 2025 | Travel and Lodging travel to AVENTURA, FL | $32.94 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 13 companies. The companies reported $1,171,556 in research payments for these studies, mostly to the institutions running them.
- NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Abbott Laboratories - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - Safety and Efficacy of the Omnipod 5 SmartAdjust 2.0 System Compared to the Omnipod 5 System in Individuals with Type 1 or Type 2 Diabetes
Insulet Corporation - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
Amgen Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05872620 - CIP336 Fiasp
Medtronic, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.